|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: UTP23 |
Gene summary for UTP23 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | UTP23 | Gene ID | 84294 |
| Gene name | UTP23 small subunit processome component | |
| Gene Alias | C8orf53 | |
| Cytomap | 8q24.11 | |
| Gene Type | protein-coding | GO ID | GO:0000462 | UniProtAcc | Q9BRU9 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 84294 | UTP23 | C43 | Human | Oral cavity | OSCC | 2.88e-09 | 2.12e-01 | 0.1704 |
| 84294 | UTP23 | C46 | Human | Oral cavity | OSCC | 4.54e-11 | 1.69e-01 | 0.1673 |
| 84294 | UTP23 | C51 | Human | Oral cavity | OSCC | 8.52e-11 | 6.85e-01 | 0.2674 |
| 84294 | UTP23 | C57 | Human | Oral cavity | OSCC | 9.84e-08 | 2.75e-01 | 0.1679 |
| 84294 | UTP23 | C06 | Human | Oral cavity | OSCC | 1.27e-08 | 1.03e+00 | 0.2699 |
| 84294 | UTP23 | C08 | Human | Oral cavity | OSCC | 4.26e-21 | 4.64e-01 | 0.1919 |
| 84294 | UTP23 | C09 | Human | Oral cavity | OSCC | 3.85e-05 | 1.45e-01 | 0.1431 |
| 84294 | UTP23 | LN22 | Human | Oral cavity | OSCC | 4.60e-03 | 2.93e-01 | 0.1733 |
| 84294 | UTP23 | LN46 | Human | Oral cavity | OSCC | 1.02e-09 | 2.60e-01 | 0.1666 |
| 84294 | UTP23 | LP17 | Human | Oral cavity | LP | 1.61e-06 | 4.63e-01 | 0.2349 |
| 84294 | UTP23 | NEOLP-3 | Human | Oral cavity | NEOLP | 3.57e-03 | 1.39e-01 | -0.0191 |
| 84294 | UTP23 | SYSMH1 | Human | Oral cavity | OSCC | 1.18e-04 | 1.74e-01 | 0.1127 |
| 84294 | UTP23 | SYSMH2 | Human | Oral cavity | OSCC | 1.18e-16 | 6.55e-01 | 0.2326 |
| 84294 | UTP23 | SYSMH3 | Human | Oral cavity | OSCC | 8.86e-31 | 7.56e-01 | 0.2442 |
| 84294 | UTP23 | SYSMH5 | Human | Oral cavity | OSCC | 2.06e-07 | 2.98e-01 | 0.0647 |
| 84294 | UTP23 | SYSMH6 | Human | Oral cavity | OSCC | 3.18e-02 | 2.63e-01 | 0.1275 |
| 84294 | UTP23 | P4_S8_cSCC | Human | Skin | cSCC | 9.58e-07 | 1.55e-01 | -0.3095 |
| 84294 | UTP23 | P5_S10_cSCC | Human | Skin | cSCC | 1.76e-05 | 9.73e-02 | -0.299 |
| 84294 | UTP23 | P1_cSCC | Human | Skin | cSCC | 2.04e-08 | 3.36e-01 | 0.0292 |
| 84294 | UTP23 | P2_cSCC | Human | Skin | cSCC | 1.26e-05 | 2.12e-01 | -0.024 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0022613111 | Esophagus | ESCC | ribonucleoprotein complex biogenesis | 365/8552 | 463/18723 | 1.74e-49 | 1.11e-45 | 365 |
| GO:0042254111 | Esophagus | ESCC | ribosome biogenesis | 252/8552 | 299/18723 | 3.27e-44 | 1.04e-40 | 252 |
| GO:003447015 | Esophagus | ESCC | ncRNA processing | 300/8552 | 395/18723 | 3.09e-35 | 3.26e-32 | 300 |
| GO:0016072110 | Esophagus | ESCC | rRNA metabolic process | 197/8552 | 236/18723 | 1.31e-33 | 1.18e-30 | 197 |
| GO:0006364110 | Esophagus | ESCC | rRNA processing | 189/8552 | 225/18723 | 4.88e-33 | 3.87e-30 | 189 |
| GO:003466012 | Esophagus | ESCC | ncRNA metabolic process | 346/8552 | 485/18723 | 4.35e-31 | 2.51e-28 | 346 |
| GO:0042274111 | Esophagus | ESCC | ribosomal small subunit biogenesis | 67/8552 | 73/18723 | 6.62e-17 | 5.38e-15 | 67 |
| GO:00905013 | Esophagus | ESCC | RNA phosphodiester bond hydrolysis | 110/8552 | 152/18723 | 1.95e-11 | 6.81e-10 | 110 |
| GO:00304904 | Esophagus | ESCC | maturation of SSU-rRNA | 45/8552 | 50/18723 | 5.07e-11 | 1.63e-09 | 45 |
| GO:00903053 | Esophagus | ESCC | nucleic acid phosphodiester bond hydrolysis | 163/8552 | 261/18723 | 3.07e-08 | 5.73e-07 | 163 |
| GO:00004623 | Esophagus | ESCC | maturation of SSU-rRNA from tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA) | 32/8552 | 37/18723 | 2.96e-07 | 4.23e-06 | 32 |
| GO:00004693 | Esophagus | ESCC | cleavage involved in rRNA processing | 24/8552 | 27/18723 | 3.48e-06 | 3.84e-05 | 24 |
| GO:00905023 | Esophagus | ESCC | RNA phosphodiester bond hydrolysis, endonucleolytic | 55/8552 | 82/18723 | 7.34e-05 | 5.51e-04 | 55 |
| GO:00004783 | Esophagus | ESCC | endonucleolytic cleavage involved in rRNA processing | 14/8552 | 15/18723 | 1.47e-04 | 9.85e-04 | 14 |
| GO:00004793 | Esophagus | ESCC | endonucleolytic cleavage of tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA) | 14/8552 | 15/18723 | 1.47e-04 | 9.85e-04 | 14 |
| GO:002261312 | Liver | Cirrhotic | ribonucleoprotein complex biogenesis | 231/4634 | 463/18723 | 3.28e-32 | 6.86e-29 | 231 |
| GO:004225412 | Liver | Cirrhotic | ribosome biogenesis | 154/4634 | 299/18723 | 1.18e-23 | 6.72e-21 | 154 |
| GO:000636412 | Liver | Cirrhotic | rRNA processing | 115/4634 | 225/18723 | 1.12e-17 | 1.64e-15 | 115 |
| GO:00160724 | Liver | Cirrhotic | rRNA metabolic process | 119/4634 | 236/18723 | 1.19e-17 | 1.70e-15 | 119 |
| GO:00344701 | Liver | Cirrhotic | ncRNA processing | 158/4634 | 395/18723 | 1.09e-11 | 6.96e-10 | 158 |
| Page: 1 2 3 4 5 6 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| UTP23 | SNV | Missense_Mutation | c.317C>A | p.Ser106Tyr | p.S106Y | Q9BRU9 | protein_coding | deleterious(0) | possibly_damaging(0.726) | TCGA-A8-A095-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR | |
| UTP23 | SNV | Missense_Mutation | novel | c.302N>T | p.Ser101Leu | p.S101L | Q9BRU9 | protein_coding | deleterious(0.01) | benign(0.193) | TCGA-VS-A958-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| UTP23 | SNV | Missense_Mutation | rs752871869 | c.694N>T | p.Arg232Trp | p.R232W | Q9BRU9 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AA-3492-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| UTP23 | SNV | Missense_Mutation | novel | c.369N>T | p.Gln123His | p.Q123H | Q9BRU9 | protein_coding | tolerated(0.23) | possibly_damaging(0.818) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| UTP23 | SNV | Missense_Mutation | c.161T>C | p.Met54Thr | p.M54T | Q9BRU9 | protein_coding | tolerated(0.4) | benign(0.313) | TCGA-AD-6895-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD | |
| UTP23 | SNV | Missense_Mutation | c.702N>T | p.Arg234Ser | p.R234S | Q9BRU9 | protein_coding | tolerated_low_confidence(0.13) | benign(0.122) | TCGA-F4-6570-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| UTP23 | SNV | Missense_Mutation | c.400N>C | p.Gly134Arg | p.G134R | Q9BRU9 | protein_coding | deleterious(0) | possibly_damaging(0.448) | TCGA-NH-A50T-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| UTP23 | insertion | Nonsense_Mutation | novel | c.241_242insAATAGTCGATTTTT | p.Leu81GlnfsTer2 | p.L81Qfs*2 | Q9BRU9 | protein_coding | TCGA-AM-5820-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| UTP23 | SNV | Missense_Mutation | novel | c.458A>C | p.Lys153Thr | p.K153T | Q9BRU9 | protein_coding | tolerated(0.31) | benign(0.001) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| UTP23 | SNV | Missense_Mutation | c.702A>T | p.Arg234Ser | p.R234S | Q9BRU9 | protein_coding | tolerated_low_confidence(0.13) | benign(0.122) | TCGA-AJ-A2QO-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |